473
Participants
Start Date
March 26, 2013
Primary Completion Date
July 31, 2019
Study Completion Date
July 31, 2019
Lacosamide
"Strength: Lacosamide (LCM) 50 mg, LCM 100 mg~Formulation: Tablet~Frequency: twice daily during the study period (until the date of approval)~At the completion of EP0008 \[NCT01710657\], all subjects who choose to enroll in EP0009 will be taking a dose of Lacosamide 200 mg/day. At the beginning of EP0009, the investigator may maintain the LCM dose or increase or decrease the dose. During the Treatment Period, the investigator will be allowed to increase or decrease the dose of LCM to optimize tolerability and seizure reduction. The LCM dose may be decreased to 100 mg/day or increased, no faster than 100 mg/day per week, up to 400 mg/day."
86026, Beijing
86027, Beijing
86015, Changchun
86005, Chengdu
86032, Chengdu
86006, Chongqing
86031, Dalian
86007, Guangzhou
86008, Guangzhou
86009, Guangzhou
86013, Guangzhou
86016, Guangzhou
86014, Hangzhou
86010, Harbin
86019, Jinan
86004, Kunming
86011, Nanchang
86012, Nanchang
86028, Nanjing
86003, Qingdao
86001, Shanghai
86023, Shanghai
86025, Shanghai
86020, Shijiazhuang
86022, Suzhou
86002, Taiyuan
86018, Wuhan
86024, Wuhan
86017, Xi'an
86029, Xiamen
81056, Asaka
81013, Fukuoka
81054, Fukuoka
81057, Hachinohe
81027, Hamamatsu
81004, Himeji
81018, Hiroshima
81019, Iwanuma
81012, Kagoshima
81033, Kitakyushu
81017, Kobe
81024, Kodaira
81010, Kokubunji
81032, Kōshi
81014, Kurume
81047, Kyoto
81035, Nagakute
81028, Nagoya
81029, Nagoya
81040, Nara
81007, Neyagawa
81002, Niigata
81005, Okayama
81011, Saitama
81042, Sakai
81025, Sapporo
81053, Sapporo
81009, Sayama
81021, Shimotsuke
81022, Shimotsuke
81026, Shinjuku
81003, Shizuoka
81023, Suita
81051, Suita
81006, Toyonaka
81050, Ube
81001, Yamagata
UCB Japan Co. Ltd.
INDUSTRY
UCB Pharma SA
INDUSTRY